<DOC>
	<DOC>NCT00686998</DOC>
	<brief_summary>This study is designed to assess the effects of AZD 2624 in patients with schizophrenia</brief_summary>
	<brief_title>Phase IIA Study in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Females of nonchildbearing potential Diagnosis of Schizophrenia Clinically relevant disease and /or abnormalities. Alcohol or substance abuse not in remission Enrollment in another investigational study within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>